NGFR and Alzheimer disease: In this study, we report the application of a p75NTR-based therapy in a human disease setting through a 26-week randomized, double-blind, parallel-group phase 2a safety and exploratory efficacy trial of LM11A-31 in participants with mild to moderate AD dementia.